{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008054","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.113087+00:00","generated_at":"2026-06-02T01:04:28.014987+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Passage Bio Q1 net loss $16.7M, cash $104.5M; PBFT02 shows sustained CSF PGRN in 2 patients","bullets":["Net loss of $16.7M ($0.30/shr) vs $34.3M a year ago; cash $104.5M, runway through Q4 2025.","Dose 1 PBFT02 elevated CSF progranulin (21.7–27.3 ng/mL) at 6 months in 2 FTD-GRN patients.","Completed dosing Cohort 1 (n=5) in upliFT-D trial; 6-month safety/biomarker data due 2H 2024.","Plan to initiate Cohort 2 dosing in 1H 2024; FDA feedback sought for FTD-C9orf72 indication.","Raised $8.7M net under ATM facility in Q1 2024; R&D expenses $11.5M, G&A $6.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008054","json":"https://secwatch.observer/filing/0001558370-24-008054.json","markdown":"https://secwatch.observer/filing/0001558370-24-008054.md","text":"https://secwatch.observer/filing/0001558370-24-008054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024008054/0001558370-24-008054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024008054/pasg-20240514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:04:28.014987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7c8c676fcf76e1001b3d0801f37b46901c60aaf","claim":"Passage BIO, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $16.7 million, or $0.30 per basic and diluted share.","evidence_excerpt":"Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837024008054/0001558370-24-008054-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $16.7 million, or $0.30 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}